A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Trial Details

NCT ID

NCT06618287

Phase

PHASE1 / PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• BMS-986507
• Osimertinib
• Pembrolizumab
• Nivolumab
• Pumitamig

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Miami, Florida, United States|25.77427,-80.19366
• Maywood, Illinois, United States|41.8792,-87.84312
• Iowa City, Iowa, United States|41.66113,-91.53017
• Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

• Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
• Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Participants must have a life expectancy of at least 3 months at the time of the first dose.
• Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in ex…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.